SH2B3 and colorectal carcinoma: Interrogation of TCGA and Broad Institute sequence data from colorectal adenocarcinomas34, 35, 36 did not identify an excess of somatic mutations in SH2B3 (0.69% of samples carry deleterious mutations or copy number variations), suggesting that SH2B3 mutations are not drivers in CRC progression33.